English | 简体中文 | 繁體中文 | 한국어 | 日本語
Thursday, 1 February 2018, 17:20 JST
Share:
    

Source: Eisai
Eisai: Primary Endpoint Met in Phase II / III Clinical Study of Investigational Parkinson's Disease Treatment Safinamide in Japan

TOKYO, Feb 1, 2018 - (JCN Newswire) - Eisai Co., Ltd. and Meiji Seika Pharma Co., Ltd. announced today that the primary endpoint was met in a Phase II/III clinical study on the investigational Parkinson's disease treatment ME2125 (safinamide mesylate, "safinamide") in patients with Parkinson's disease. Having received the results of the study, Meiji plans to submit a marketing authorization application for safinamide in Japan during 2018.

The study was a multicenter, double-blind, placebo-controlled, randomized, parallel group study to evaluate the efficacy and safety of two doses of safinamide (50 and 100 mg, once a day for 24 weeks) administered orally as add-on therapy in Japanese patients with Parkinson's disease with wearing-off phenomenon(1) who are currently receiving levodopa. The study was conducted by Meiji in Japan in accordance with the licensing agreement between the two companies. In this study, the primary endpoint was the change in mean daily "on" time(2) from baseline to 24 weeks of the treatment phase.

From the preliminary results of the study, the safinamide group (50 and 100 mg/day, respectively) demonstrated a statistically significant increase in "on" time compared to the placebo group. In addition, the four most commonly reported adverse events in the safinamide groups in the study were nasopharyngitis, dyskinesia, fall, and contusion.

Under the agreement signed between Eisai and Meiji in March 2017, Eisai obtained the exclusive rights to safinamide to market in Japan and to develop and market in Asia(3). Meiji will continue the clinical trials that it is currently conducting and submit a marketing authorization application for the drug in Japan. Meanwhile, Eisai will conduct clinical trials for seeking regulatory approval, and make the applications in Asia.

Through the development of safinamide, Eisai and Meiji will make further contributions to address the diversified needs of, and increase the benefits provided to, Parkinson's disease patients and their families.

(1) Wearing off phenomenon: As the disease progresses, levodopa's duration of effect ("on" time) decreases, and Parkinson's disease symptoms return before the next dose
(2) On time: Period of time in which Parkinson's disease symptoms are suppressed due to the effect of levodopa
(3) South Korea, Taiwan, Brunei, Cambodia, Laos, Malaysia, the Philippines, Indonesia, Thailand, Vietnam, Myanmar, Singapore, Hong Kong, Macao

Contact:
Eisai
Public Relations Department,
Eisai Co., Ltd.
+81-3-3817-5120


Topic: Press release summary
Source: Eisai

Sectors: BioTech
https://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2022 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.

 

Eisai Releated News
2022年6月24日 11時00分 JST
エーザイ、顧みられない熱帯病制圧に向けた官民パートナーシップ「キガリ宣言」に署名
Friday, 24 June 2022, 11:55 JST
Eisai Signs the Public-Private Partnership "Kigali Declaration" for Eliminating Neglected Tropical Diseases
2022年6月23日 12時00分 JST
エーザイ、東京都文京区による2022年度認知症検診事業において、「のうKNOW」を活用した脳の健康度測定を実施
Wednesday, 22 June 2022, 14:05 JST
Eisai Publishes Potential Economic Value of Investigational Lecanemab in Peer-Reviewed Neurology and Therapy Journal
2022年6月22日 11時00分 JST
エーザイ、「レカネマブ」の潜在的な経済価値について査読学術専門誌Neurology and Therapy誌に掲載
More news >>
Copyright © 2022 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Cookies Policy | Privacy Policy | Disclaimer | Terms of Use | RSS
US: +1 214 890 4418 | Beijing: +86 400 879 3881 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575